<DOC>
	<DOCNO>NCT01037218</DOCNO>
	<brief_summary>Randomized , placebo-controlled , double-blind , parallel design , Phase 3 study evaluate safety efficacy udenafil , orally administer , potent selective inhibitor PDE-5 versus placebo treatment subject erectile dysfunction ( ED ) .</brief_summary>
	<brief_title>Treatment Erectile Dysfunction II</brief_title>
	<detailed_description>Multi-center , randomize , double-blind , placebo-controlled , parallel-group design , Phase 3 pivotal study investigate efficacay safety 50 mg , 100 mg 150 mg udenafil tablet compare placebo men ED . This study consist 4-week , treatment free run-in period follow treatment period 12 week , on-demand dose regimen .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Male , least 19 year age Stable monogamous relationship least 6 month consent female partner least 19 year age , vaginal intercourse require study activity History ED ( clinically define inability attain maintain erection penis sufficient permit satisfactory sexual intercourse ) least 3 month duration Partner pregnant lactate History newonset symptomatic coronary artery disease within last 3 month history myocardial infarction cardiac surgical procedure within six month Cardiac arrhythmia require antiarrhythmic treatment Symptomatic congestive heart failure Taking nitrate medication form Uncontrolled diabetes ( HbA1c ≥ 13 % ) Hypersensitivity phosphodiesterase type 5 ( PDE5 ) inhibitor Viagra® , Cialis® Levitra® Previously fail respond PDE5 inhibitor Viagra® , Cialis® Levitra®</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>